Sulfasalazine and renal tubular function: lack of an effect.
Sulfasalazine (SASP) is frequently used in the treatment of chronic inflammatory bowel disease (IBD), particularly colitis. Because the drug poses a theoretical risk for renal tubular damage, 26 patients, 8-18 years of age, with Crohn's ileocolitis were studied. Thirteen children were receiving SASP while 13 served as disease controls. Renal tubular function was assessed by measurement of urinary beta 2-microglobulin and n-acetylglucosaminidase activity. No abnormalities were found on routine measurement of renal function. Similarly, urinary beta 2-microglobulin and n-acetylglucosaminidase activities were within normal limits for patients receiving SASP, as well as for disease controls. Although there is a theoretical risk for renal tubular damage from the prolonged use of SASP, this study would suggest that IBD patients receiving the drug are at no greater risk for renal injury than their counterparts not receiving the medication.
Koutras
A
A
Daum
F
F
Das
K M
KM
Markowitz
J
J
Duffy
L
L
Aiges
H
H
Atkinson
M
M
Fisher
S E
SE
D000293:Adolescent; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy*; D004848:Epithelium / Q000187:drug effects; D006801:Humans; D007677:Kidney Function Tests; D007684:Kidney Tubules / Q000187:drug effects*; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use; D001613:beta 2-Microglobulin / Q000032:analysis
D001613:beta 2-Microglobulin; D012460:Sulfasalazine